Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | JAK3 |
| Variant | Q988P |
| Impact List | missense |
| Protein Effect | gain of function |
| Gene Variant Descriptions | JAK3 Q988P lies within protein kinase domain 2 of the Jak3 protein (UniProt.org). Q988P confers a gain of function to the Jak3 protein as demonstrated by constitutive JAK/STAT pathway activation (PMID: 37712558, PMID: 39033228), increased c-Myc and S6 phosphorylation and Pim1 expression (PMID: 39033228), and cytokine-independent growth in culture (PMID: 37712558). |
| Associated Drug Resistance | |
| Category Variants Paths |
JAK3 mutant JAK3 act mut JAK3 Q988P |
| Transcript | NM_000215.4 |
| gDNA | chr19:g.17831243T>G |
| cDNA | c.2963A>C |
| Protein | p.Q988P |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| XM_047438786.1 | chr19:g.17831243T>G | c.2963A>C | p.Q988P | RefSeq | GRCh38/hg38 |
| NM_000215.4 | chr19:g.17831243T>G | c.2963A>C | p.Q988P | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| JAK3 Q988P | hematologic cancer | sensitive | LGH447 | Preclinical - Cell culture | Actionable | In a preclinical study, LGH447 inhibited viability and proliferation of transformed cells expressing JAK3 Q988P in culture (PMID: 39033228). | 39033228 |
| JAK3 Q988P | hematologic cancer | decreased response | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing JAK3 Q988P were less sensitive to Jakafi (ruxolitinib) treatment compared to cells expressing JAK3 M511I in culture (PMID: 37712558). | 37712558 |
| JAK3 Q988P | hematologic cancer | sensitive | Tofacitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Xeljanz (tofacitinib) inhibited growth of transformed cells expressing JAK3 Q988P in culture (PMID: 37712558). | 37712558 |